No clear answer
Lamotrigine: reduce relapses and new lesions in secondary progressive MS
secondary progressive MS · Axonal protection / ion channels / excitotoxicity
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
Human genetics
Genes linked to MS that these medicines act on: SCN3A
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Lamotrigine, phase 2 | Phase 2 | 120 | 2005 | Missed its main goal The mean change in partial (central) cerebral volume per year was -3.18 mL (SD -1.25) in the lamotrigine group and -2.48 mL (-0.97) in the placebo group (difference -0.71 mL, 95% CI -2.56 to 1.15; p=0.40). Paper abstract | Not counted: not randomised |
Counted: 0. Will count later: 0. Not counted: 1.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as No clear answer
Related hypotheses
- Amiloride: protect nerve tissue in secondary progressive MS
- Fluoxetine: protect nerve tissue in secondary progressive MS
- Riluzole: protect nerve tissue in secondary progressive MS
- Nerispirdine: repair myelin in secondary progressive MS
- Dronabinol: slow disability worsening in secondary progressive MS
- Epoetin beta: slow disability worsening in secondary progressive MS
- Fluoxetine: slow disability worsening in secondary progressive MS
- Amiloride: reduce relapses and new lesions in secondary progressive MS
- Fluoxetine: reduce relapses and new lesions in secondary progressive MS
- Riluzole: reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources.